Research and Markets has announced the addition of the "Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H2 2016" report to their offering.
Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted pipeline therapeutics.
The report provides comprehensive information on the Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved in Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Ephrin Type A Receptor 2 Overview
- Therapeutics Development
- Pipeline Products for Ephrin Type A Receptor 2 - Overview
- Pipeline Products for Ephrin Type A Receptor 2 - Comparative Analysis
- Ephrin Type A Receptor 2 - Therapeutics under Development by Companies
- Ephrin Type A Receptor 2 - Therapeutics under Investigation by Universities/Institutes
- Ephrin Type A Receptor 2 Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Ephrin Type A Receptor 2 - Products under Development by Companies
- Ephrin Type A Receptor 2 - Products under Investigation by Universities/Institutes
- Ephrin Type A Receptor 2 - Companies Involved in Therapeutics Development
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Ltd
- Galapagos NV
- Merrimack Pharmaceuticals Inc
For more information about this report visit http://www.researchandmarkets.com/research/q7sh74/ephrin_type_a
View source version on businesswire.com: http://www.businesswire.com/news/home/20170126005860/en/